Refused claims deepen clouds surrounding PCSK9 inhibitors

Insurers denied coverage for nearly 80,000 patient claims for cholesterol-lowering drugs known as PCSK9 inhibitors in 2017, according to new findings.

The non-profit Institute for Patient Access (IfPA) released a new Health Plan Coverage Report Card that shows the outcome of PCSK9 inhibitor claims for Medicare, Medicaid, Medicaid managed care, and commercial managed care organizations.

"This report shows that health plans are cutting costs at patients’ expense"